Publications by authors named "Ludger Rose"

Claim this Profile
analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders.
Valeria Sordi, Paolo Monti, Vito Lampasona, Raffaella Melzi, Silvia Pellegrini, Ludger Rose

Front Endocrinol (Lausanne)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.
Lorenzo Piemonti, Bart Keymeulen, Pieter Gillard, Thomas Linn, Emanuele Bosi, Ludger Rose

Diabetes Obes Metab· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.
Victoria E R Parker, Thuong Hoang, Heike Schlichthaar, Fraser W Gibb, Barbara Wenzel, Ludger Rose

Diabetes Obes Metab· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving HbA1c Control in Type 1 or Type 2 Diabetes Using Flash Glucose Monitoring: A Retrospective Observational Analysis in Two German Centres.
Ludger Rose, Gerhard Klausmann, Alexander Seibold

Diabetes Ther· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9).
Wendy S Lane, Elena Favaro, Naveen Rathor, Hak C Jang, Maiken I S Kjærsgaard, Ludger Rose

Diabetes Care· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials.
Ludger Rose, Takashi Kadowaki, Thomas R Pieber, Kristine Buchholtz, Magnus Ekelund

Diabetes Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
John B Buse, Anders L Carlson, Mitsuhisa Komatsu, Ofri Mosenzon, Ludger Rose

Diabetes Obes Metab· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.
Ildiko Lingvay, Cyrus V Desouza, Katarina S Lalic, Ludger Rose, Thomas Hansen

Diabetes Care· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Helena W Rodbard, Ildiko Lingvay, John Reed, Raymond de la Rosa, Ludger Rose

J Clin Endocrinol Metab· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Chantal Mathieu, Bruce W Bode, Edward Franek, Athena Philis-Tsimikas, Ludger Rose

Diabetes Obes Metab· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
David Russell-Jones, Bruce W Bode, Christophe De Block, Edward Franek, Simon R Heller, Ludger Rose

Diabetes Care· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Vanita R Aroda, Stephen C Bain, Bertrand Cariou, Milivoj Piletič, Ludger Rose

Lancet Diabetes Endocrinol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Data Collection Regarding Titration Algorithms for Insulin Glargine in Patients With Type 2 Diabetes Mellitus.
Andreas Pfützner, Bernd Stratmann, Klaus Funke, Harald Pohlmeier, Ludger Rose

J Diabetes Sci Technol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: a randomized open-label study.
Thomas Danne, Thomas Forst, Jürgen Deinhard, Ludger Rose, Elisabeth Moennig

J Diabetes Sci Technol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis